Trade

with

ARIAD Pharmaceuticals Inc
(NASDAQ: ARIA)
AdChoices
5.75
+0.16
+2.86%
After Hours :
-
-
-

Open

5.65

Previous Close

5.59

Volume (Avg)

3.29M (7.42M)

Day's Range

5.55-5.82

52Wk Range

2.15-9.83

Market Cap.

1.05B

Dividend Rate ( Yield )

-

Beta

1.52

Shares Outstanding

187.01M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 45.56M

    • Net Income

    • -274.16M

    • Market Cap.

    • 1.05B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -504.79

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.52

    • Forward P/E

    • -7.72

    • Price/Sales

    • 21.23

    • Price/Book Value

    • 8.52

    • Price/Cash flow

    • -5.29

      • EBITDA

      • -269.43M

      • Return on Capital %

      • -53.25

      • Return on Equity %

      • -114.34

      • Return on Assets %

      • -53.25

      • Book Value/Share

      • 0.66

      • Shares Outstanding

      • 187.01M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 10.50

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.72

        • Cashflow Estimate

        • -0.58

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -13.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 45.11

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 73.87

            • 82.75

            • Pre-Tax Margin

            • -503.73

            • 39.38

            • Net Profit Margin

            • -504.79

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 95.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -8,317.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 2.42

              • 0.76

              • Current Ratio

              • 5.09

              • 2.92

              • Quick Ratio

              • 4.95

              • 2.35

              • Interest Coverage

              • -370.58

              • 38.02

              • Leverage Ratio

              • 4.01

              • 2.21

              • Book Value/Share

              • 0.66

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.36

                • 277.78

                • P/E Ratio 5-Year High

                • -19.11

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.28

                • 124.82

                • Price/Sales Ratio

                • 22.03

                • 9.35

                • Price/Book Value

                • 8.83

                • 8.50

                • Price/Cash Flow Ratio

                • -5.29

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -114.34

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -53.25

                        (-54.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -62.69

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 15.60

                      • 1.48

                      • Asset Turnover

                      • 0.11

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -273.57M
                      Operating Margin
                      -600.44
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -5.29
                      Ownership

                      Institutional Ownership

                      66.93%

                      Top 10 Institutions

                      41.09%

                      Mutual Fund Ownership

                      30.36%

                      Float

                      89.69%

                      5% / Insider Ownership

                      2.13%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        9,117,251

                      • 0.00

                      • 4.88

                      • Franklin Biotechnology Discovery

                      •  

                        3,387,100

                      • -5.23

                      • 1.81

                      • SPDR® S&P Biotech ETF

                      •  

                        2,965,828

                      • 0.00

                      • 1.70

                      • Vanguard Small Cap Index

                      •  

                        2,924,722

                      • -0.22

                      • 1.56

                      • Vanguard Total Stock Mkt Idx

                      •  

                        2,752,220

                      • 0.16

                      • 1.47

                      • iShares Russell 2000 (AU)

                      •  

                        2,537,339

                      • -0.90

                      • 1.45

                      • iShares Nasdaq Biotechnology

                      •  

                        2,436,684

                      • -1.85

                      • 1.40

                      • Pictet-Biotech

                      •  

                        2,010,831

                      • 0.07

                      • 1.10

                      • Vanguard Small Cap Growth Index Fund

                      •  

                        1,975,871

                      • -2.04

                      • 1.06

                      • Fidelity® Independence Fund

                      •  

                        1,782,600

                      • 0.00

                      • 0.95

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        13,380,046

                      • 0.00%

                      • 7.16

                      • Sarissa Capital Management LP

                      •  

                        12,850,000

                      • +7.08%

                      • 6.87

                      • Vanguard Group, Inc.

                      •  

                        10,655,939

                      • +2.62%

                      • 5.70

                      • BlackRock Fund Advisors

                      •  

                        6,439,785

                      • +78.53%

                      • 3.45

                      • State Street Corp

                      •  

                        5,772,991

                      • +19.08%

                      • 3.09

                      • Franklin Advisers, Inc.

                      •  

                        5,038,427

                      • -2.24%

                      • 2.70

                      • Camber Capital Management LLC

                      •  

                        5,000,000

                      • +66.67%

                      • 2.68

                      • Renaissance Technologies Corp

                      •  

                        4,399,981

                      • +95.66%

                      • 2.35

                      • AQR Capital Management LLC

                      •  

                        3,882,830

                      • +320.44%

                      • 2.08

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling w...moreith small molecules. The Company’s first approved cancer medicine, Iclusig® (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be...more readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company’s competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.lessless

                      Key People

                      Dr. Harvey J. Berger,M.D.

                      Founder/CEO/Chairman of the Board/President/Director

                      Edward M. Fitzgerald

                      CFO/Chief Accounting Officer/Executive VP/Treasurer

                      Martin J. Duvall

                      Executive VP/Other Executive Officer

                      Dr. Athanase Lavidas,PhD

                      Director

                      Jay R. Lamarche

                      Director

                      • ARIAD Pharmaceuticals Inc

                      • 26 Landsdowne Street

                      • Cambridge, MA 02139-4234

                      • USA.Map

                      • Phone: +1 617 494-0400

                      • Fax: -

                      • ariad.com

                      Incorporated

                      1991

                      Employees

                      307

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: